Ocular Therapeutix (NASDAQ: OCUL) insider plans 3,296-share sale

Rhea-AI Filing Summary

OCULAR THERAPEUTIX, INC. (OCUL) is the issuer of common stock that Jeffrey S. Heier plans to sell under Rule 144. A notice covers a proposed sale of 3,296 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $35,532.20, tied to restricted stock vesting under a registered plan. The filing also reports that Heier sold 3,018 common shares over the prior three months for $24,745.19.

Key Figures

Shares proposed to be sold: 3,296 shares of common stock Aggregate market value of proposed sale: $35,532.20 CUSIP or identifying number: 219615868 +3 more

6 metrics

Shares proposed to be sold 3,296 shares of common stock Proposed Rule 144 sale by Jeffrey S. Heier

Aggregate market value of proposed sale $35,532.20 Value for 3,296 OCUL common shares in proposed Form 144 sale

CUSIP or identifying number 219615868 Security identifier listed for OCULAR THERAPEUTIX, INC. common stock

Vesting date for restricted stock 08/22/2026 Restricted stock vesting under a registered plan related to the proposed sale

Shares sold in prior 3 months 3,018 shares of common stock Sale by Jeffrey S. Heier on 05/26/2026

Aggregate value of prior 3-month sale $24,745.19 Total value for 3,018 OCUL common shares sold on 05/26/2026

Key Terms

Rule 144, Restricted Stock Vesting Under a Registered Plan, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting Under a Registered Plan financial

"Common | 08/22/2026 | Restricted Stock Vesting Under a Registered Plan |"

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 3296 | 35532.20 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does the Form 144 filing disclose for OCUL by Jeffrey S. Heier?

The notice states that Jeffrey S. Heier plans to sell 3,296 shares of OCULAR THERAPEUTIX, INC. common stock under Rule 144, with an aggregate market value of $35,532.20, in connection with restricted stock vesting under a registered plan.

How many OCUL shares are proposed to be sold in this Form 144?

The proposed transaction covers 3,296 common shares of OCULAR THERAPEUTIX, INC. These shares are associated with restricted stock vesting under a registered plan and are to be sold through Morgan Stanley Smith Barney LLC.

What is the aggregate market value of the OCUL shares to be sold?

The filing lists an aggregate market value of $35,532.20 for the 3,296 OCUL common shares proposed to be sold. This figure reflects the market value used for the Form 144 notice.

Which broker is handling the planned OCUL share sale under Form 144?

The planned sale of 3,296 OCUL common shares is to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, as disclosed in the Form 144 filing.

What prior OCUL share sales by Jeffrey S. Heier are disclosed in the last 3 months?

The filing reports that Jeffrey S. Heier sold 3,018 OCUL common shares on 05/26/2026 for a total value of $24,745.19 during the preceding three months.

What is the nature of the OCUL securities being sold by Jeffrey S. Heier?

The securities are common stock of OCULAR THERAPEUTIX, INC., and the proposed Form 144 sale relates to restricted stock vesting under a registered plan, with 3,296 shares covered by the current notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 04:44 PM Accepted by SEC EDGAR 08/24/2026 - 04:44 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001653082
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	OCULAR THERAPEUTIX, INC.
SEC File Number	001-36554
Address of Issuer	14 CROSBY DRIVE, 3RD FLOOR BEDFORD MASSACHUSETTS 01730
Phone	781-357-4000
Name of Person for Whose Account the Securities are To Be Sold	JEFFREY S. HEIER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3296	35532.20	219615868	08/24/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/22/2026	Restricted Stock Vesting Under a Registered Plan	Issuer			3296	08/22/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JEFFREY S. HEIER 15 Crosby Drive Bedford MA 01730	Common	05/26/2026	3018	24745.19

144: Remarks and Signature

Remarks
Date of Notice	08/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jeffrey Heier
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)